Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype

Pharmacogenetics

Volumn 10, Issue 2, 2000, Pages 171-182

  O'Neil, William M ^a   Drobitch, Robert K ^a   MacArthur, Rodger D ^a   Farrough, Marti J ^a   Doll, Mark A ^b   Fretland, Adrian J ^b   Hein, David W ^b   Crane, Lawrence R ^a   Svensson, Craig K ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Arylamine N acetyltransferase; Genotype; HIV infections acquired immunodeficiency syndrome; Phenotype

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOKINE; DAPSONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACETYLATOR PHENOTYPE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034105165     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200003000-00009     Document Type: Article

References (31)

1. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5:1237-1257.
2. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5:341-347.
3. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693-699.
4. Butler MA, Lang NP, Young JF, Caporaso NE, Vincis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-127.
5. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS 1994; 8:333-337.
6. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999; 9:123-127.
7. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Muller A, Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab Rev 1999; 31:489-502.
8. Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 1989; 28:389-395.
9. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1993; 45:1277-1282.
10. Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994; 4:166-170.
11. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996a; 15:9-50.
12. Cribb AE, Nuss CE, Alberts DW, Lamphere DB, Grant DM, Grossman SJ, Spielberg SP. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1996b; 9:500-507.
13. Deitz AC, Doll MA, Hein DW. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NAT1) alleles. Anal Biochem 1997; 253:219-224.
14. Deloménie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F. Jacqz-Aigrain E, et al. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994; 38:581-582.
15. Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem 1995; 231:413-420.
16. Drobitch RK, Tomilo M, Svensson CK. Immunomodulation and drug acetylation: influence of the immunomodulator tilorone on hepatic, renal and blood N-acetyltransferase activity and on hepatic cytosolic acetyl coenzyme A content. Biochem Pharmacol 1992; 43:1643-1648.
17. Godfried MH, van der Poll T, Weverling GJ, Mulder JW, Jansen J, van Deventer SJ, Sauerwein HP. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994; 169:739-745.
18. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376:61-70.
19. Grunfeld C, Feingold KR. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992; 122:749-753.
20. Jaffe H, Ammann A, Abrams D, Lewis B, Golden J. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; ii:1109-1111.
21. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60:62-67.
22. Kilpatrick LE, Polin RA, Douglas SD, Corkey BE. Hepatic metabolic alterations in rats treated with low-dose endotoxin and aspirin: an animal model of Reye's syndrome. Metabolism 1989; 38:73-77.
23. Koda R, Dubé M, Li W, Chatterjee D, Stansell J, Sattler F. Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. J Clin Pharmacol 1999; 39:268-274.
24. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53:529-535.
25. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126:1393-1407.
26. O'Neil W, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62:261-271.
27. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11:969-988.
28. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49:13-17.
29. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-184.
30. Zheng W, Deitz AC, Campbell DR, Wen W-Q, Cerhan JR, Sellers TA, et al. N-acetyltransferase 1 (NAT1) genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8:233-239.
31. Zuidema J, Hilbers-Modderman ES, Merkus FW. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11:299-315.